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Caveolin-1 is a major structural component of raft
structures within the plasma membrane and has
been implicated as a regulator of cellular signal
transduction with prominent expression in adipo-
cytes. Here, we embarked on a comprehensive char-
acterization of the metabolic pathways dysregulated
in caveolin-1 null mice. We found that these mice
display decreased circulating levels of total and
high molecular weight adiponectin and a reduced
ability to change substrate use in response to
feeding/fasting conditions. Caveolin-1 null mice are
extremely lean but retain muscle mass despite lipo-
dystrophy and massive metabolic dysfunction.
Hepatic gluconeogenesis is chronically elevated,
while hepatic steatosis is reduced. Our data suggest
that the complex phenotype of the caveolin-1 null
mouse is caused by alteredmetabolic andmitochon-
drial function in adipose tissue with a subsequent
compensatory response driven mostly by the liver.
This mouse model highlights the central contribu-
tions of adipose tissue for system-wide preservation
of metabolic flexibility.
INTRODUCTION
Caveolin-1 is an important structural component of caveolae,
omega-shaped lipid rafts rich in cholesterol and sphingolipids
(Drab et al., 2001). These plasma membrane compartments
facilitate the interaction of receptors with downstream effectors
and are found in many different cell types, but most prominently
in endothelial cells as well as in adipocytes, where caveolae can
comprise up to 20%–30% of total plasma membrane area (Fan
et al., 1983). In addition to signaling, caveolin-1 also plays an
important role in intracellular cholesterol and sphingolipid trans-
port (Liu et al., 2002; Sonnino and Prinetti, 2009).
Mice lacking caveolin-1 display a variety of phenotypes. While
the mice are phenotypically nearly normal in the unchallenged
state, they have an increased propensity for malignant transfor-Cell Mmation (Williams and Lisanti, 2005). Metabolically, earlier studies
show that they have reduced whole-body fat mass, elevated
triglyceride levels, elevated postprandial free fatty acid (FFA)
levels, lower adiponectin levels, and a blunted response to
b3-adrenergic receptor (b3-AR) stimulation (Cohen et al., 2004;
Razani et al., 2002). Moreover, Cohen et al. demonstrate that
caveolin-1 is necessary for appropriate insulin signaling selec-
tively in adipose tissue, but not in muscle or liver (Cohen et al.,
2003). However, a more detailed metabolic characterization
has not yet been performed on these mice.
Our past work focused on metabolic flexibility of adipose
tissue. Metabolic flexibility refers to the ability of adipocytes to
rapidly adapt to changes in metabolic state and to activate
compensatory cellular pathways enabling them to appropriately
buffer excess influx and consumption of calories, thereby main-
taining systemic energy homeostasis. This functional definition
of metabolic flexibility is overlapping with the description that
other groups in the field have used (Sparks et al., 2009). We
have recently shown that mice with a transgene-mediated over-
production of adiponectin display enhancedmetabolic flexibility.
These mice exhibit increased sensitivity to b3-AR agonists and
increased mitochondrial function (Asterholm and Scherer,
2010). In many ways, mice lacking caveolin-1 display the oppo-
site phenotype, including a decreased sensitivity to b3-AR
agonists. Here, we aim to carefully dissect the individual compo-
nents that lead to the metabolic phenotype of caveolin-1 null
mice. We found that caveolin-1 deficiency leads to substantial
metabolic alterations, including a prominent metabolic inflexi-
bility and an increase in hepatic glucose production. Our data
highlight that metabolic dysregulation at the level of adipose
tissue is the major driving force for the complex systemic
changes observed in caveolin-1 null mice.
RESULTS
Caveolin-1 Null Mice Have Lower Plasma Adiponectin
Levels
We have previously observed that mice overexpressing adipo-
nectin displayed elevated caveolin-1 levels in adipocytes
(Combs et al., 2004). Furthermore, an initial phenotypic charac-
terization of the caveolin-1 null mouse showed some degree of
metabolic impairment, even though the underlying mechanistic
reasons were not understood at the time (Cohen et al., 2003,etabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inc. 171
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Figure 1. Caveolin-1 Null Mice Display Reduced Circulating Adiponectin Levels and Reduced Sensitivity to b3-AR Agonist
(A) mRNA and protein levels of adiponectin in 3-month-old male mice (n = 7–11 per group).
(B) Circulating levels of adiponectin in 2-month-old mice (n = 10–12 per group).
(C) Adiponectin complex distribution in male mice matched for total levels of adiponectin (n = 3 per group).
(D and E) FFA and insulin response to b3-AR agonist (1 mg/kg i.p.) in 2-month-old male mice (n = 4–5 per group). The error bars indicate SEM.
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Caveolin-1 and Metabolic Flexibility2004; Razani et al., 2002). Our recent work on the adipocyte-
derived secretory protein adiponectin indicated that mice
overexpressing adiponectin showed increased ‘‘metabolic
flexibility,’’ i.e., an ability to adjust effectively to changing total
nutrient availability and/or lipid or carbohydrate as primary fuel
source (Asterholm and Scherer, 2010). We therefore tested
whether the metabolic phenotype of caveolin-1 null mice could
be explained through a reduction of adiponectin levels. We
assessed adiponectin expression at both mRNA and the intra-
cellular protein level as well as at the total circulating adiponectin
level and the different adiponectin isoforms. Adiponectin mRNA
levels were increased, while intracellular adiponectin protein
levels were unaltered in adipose tissue. However, total adipo-
nectin levels in circulation as well as the relative proportion of
the HMW form were significantly reduced in the caveolin-1 null
mice (Figures 1A–1C). The difference in isoform distribution
was independent of the differences in total levels, as the vari-
ability in adiponectin levels within genotypes made it possible
to match a subset of the wild-type and caveolin-1 null samples
for equal total levels. Consistent with previous observations (Co-
hen et al., 2004), caveolin-1 null mice were essentially unrespon-
sive to b3-AR agonist stimulation as judged by impaired b3-AR172 Cell Metabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inagonist-induced release of FFAs (Figure 1D). This was also asso-
ciated with impaired b3-AR agonist-mediated insulin release, an
effect directly linked to effects in the adipocyte (Grujic et al.,
1997) (Figure 1E). Caveolin-1 null mice also displayed a signifi-
cantly reduced fat mass, as previously reported (data not shown)
(Razani et al., 2002).
Reduced ‘‘Metabolic Flexibility’’ in Caveolin-1 Null Mice
Wehave previously shown that decreased adiponectin levels are
associated with reduced metabolic flexibility, as judged by the
inability to properly respond to b3-AR agonist and overall
reduced insulin sensitivity (Asterholm and Scherer, 2010). We
wanted to test whether this reduces the ability of the mouse to
adapt to other metabolic challenges, such as physiological
fast. Fasting is known to induce hepatic steatosis secondary to
the increased levels of circulating FFAs released through lipol-
ysis in adipose tissue. We assessed hepatic steatosis before
and after a 24 hr fast by computerized tomography (CT) (Aster-
holm and Scherer, 2010).Wild-typemice displayed the expected
increase in hepatic lipid accumulation, while this response was
significantly blunted in the caveolin-1 null mice (Figures 2A and
2B). An alternative test to probe metabolic flexibility is thec.
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Figure 2. Reduced Hepatic Steatosis, Reduced Response to ADF, Lower RER Variability, but Normal Levels of Fasting-Induced FFAs in the
Caveolin-1 Null Mice
Hepatic steatosis was assessed by CT measurements before and after a 24 hr fast (A) (note that the difference is plotted). (B) Representative ORO stain of livers
from 24 hr fasted mice. Hepatic steatosis was assessed after 8 weeks of HFD feeding ad libitum (C) and followed by 4 weeks HFD feeding ADF or ad libitum HFD
(D). Chow-fed mice were acclimatized to the metabolic cages for 4 days, and on the fifth day RER (E) was recorded. Male mice 3–4 months old were used for (A)–
(E) (n = 4–10 per group). (F) and (G) show the levels of circulating FFAs and glycerol in the fed state at 7 p.m.; 24 hr fasted state at 7 p.m.; and 15, 30, and 60 min
after refeeding (n = 5 per group; 12-week-old female cohorts used). The error bars indicate SEM.
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tion of 1 day of fasting followed by 1 day of ad libitum access to
food has previously been shown to remodel adipose tissue and
in fact improves whole-body metabolism in mice (Varady et al.,
2010; Varady and Hellerstein, 2007). Wild-type control mice
and caveolin-1 null mice were first fed a high-fat diet (HFD) for
8 weeks, followed by either ADF or continued ad libitum feedingCell Mfor an additional 4 weeks. Consistent with previous studies, the
caveolin-1 null mice were protected against HFD-induced
obesity (data not shown and Razani et al., 2002). The reduced
weight gain was also associated with reduced hepatic steatosis
after HFD exposure (Figure 2C). This observation is in sharp
contrast to other lipodystrophic mouse models in which the
inability to store fat causes increased ectopic lipid storage inetabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inc. 173
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Caveolin-1 and Metabolic Flexibilitythe liver (Asterholm et al., 2007). Wild-type mice benefitted from
the ADF regimen with respect to hepatic steatosis, while there
was no impact in the caveolin-1 null mice (Figure 2D). This is
not solely due to the lower baseline lipid level in the caveolin-1
null mice after HFD, since a clear increase in hepatic lipid content
in caveolin-1 null mice after HFD exposure is apparent as well
(Figure 2C). Body weights within the genotypes were similar
between ADF and the ad libitum-fed mice (WT, 37.8 ± 1.4 versus
39.1 ± 1.6, p = 0.6; andCav1/, 33.9 ± 0.8 versus 30.8 ± 1.3, p =
0.13 for ad libitum versus ADF). Liver weights in relation to body
weights were increased in caveolin-1 null mice under all condi-
tions (chow diet, HFD, HFD ADF) (see Figure S1A available
online), indicating that the liver may be a key organ that compen-
sates to maintain normal systemic metabolism.
The respiratory exchange ratio (RER) reflects preferences for
fuel utilization, with RERs near 0.7 indicating predominant use
of FFAs as energy source, whereas RERs around 1.0 reflect pref-
erential use of carbohydrates. The rate at which the RER
changes between fasting (preferential FFA use) versus fed
(enhanced carbohydrate use) is a reflection of the ‘‘metabolic
flexibility’’ of a mouse in terms of adapting to altered fuel avail-
ability. We measured the RER calculated from O2 consumption
and CO2 production data obtained in metabolic cages in
chow-fed mice. We found that the variability of RER over
a 24 hr period was reduced in the caveolin-1 null mice, i.e.,
RER remained high also during the light phase (Figure 2E). This
suggests that the caveolin-1 null mice are generally less adept
to switching fuel sources and display an increased propensity
toward carbohydratemetabolism.We also observed an increase
in food intake (Figure S1B) and an increase in O2 consumption
(Figure S1C) in the caveolin-1 null mice. In another set of mice,
we measured RER during a 24 hr fast, a state with the highest
possible rates of fatty acid oxidation, and found that RER was
higher in the caveolin-1 null mice compared to the wild-type
controls. This is consistent with a reduced capacity for whole-
body fatty acid oxidation in caveolin-1 null mice (Figure S1D).
Since caveolin-1 null mice display a lower capacity for whole-
body fatty acid oxidation and are less adept at storing excess
energy in adipose tissue compared to wild-type mice, we ex-
pected to see an increase in hepatic lipid accumulation. Surpris-
ingly, however, rather than seeing an elevation, we observed
reduced levels of lipid accumulation (Figures 2A and 2B). This
prompted us to further investigate the response to feeding/
fasting in these mice.
Normal Fasting-Induced Increase in Circulating FFAs,
but Reduced Hepatic Steatosis in the Caveolin-1 Null
Mice
Our data (Figures 1D and 1E and Cohen et al., 2004; Mattsson
et al., 2010) strongly support that the lipolytic response to b3-
AR stimulation is impaired in the caveolin-1 null mice. The direct
impact on fasting-induced lipolysis has, however, not been
examined in great detail, even though we expected to see
this process impaired as well. Surprisingly, fasting triggered
equally high FFA levels in caveolin-1 null mice as in wild-type
mice (Figure 2F), despite reduced levels of phosphorylated
hormone-sensitive lipase (HSL) (Figure S1E), with overlapping
kinetics. This clearly suggests that under normal physiological
conditions, caveolin-1 null mice do not display impaired mobili-174 Cell Metabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inzation of FFAs (Figure 2F) and have elevated triglyceride levels
(Figure S1F). A similar phenomenon is seen in b1/2/3-AR
knockout mice that also have normal lipolysis during a physio-
logical fast (Jimenez et al., 2002). Hence, the preferential use of
carbohydrates in caveolin-1 null mice and the reduced hepatic
steatosis is not a function of limited FFA availability. In fact, the
caveolin-1 null mice reached even higher glycerol levels than
the controls in the fasting state (Figure 2G), suggesting either
increased lipolysis in adipose tissue or a decreased systemic
use of glycerol.
In the fed state, insulin levels were higher in caveolin-1 null
mice, while glucose levels were comparable, and hepatic
glycogen levels were reduced (16.9 ± 4.8 versus 5.2 ± 0.7 mg/g,
p < 0.05), indicative of a degree of insulin resistance in this
system (Figures 3A and 3B). In the fasted state, the caveolin-1
null mice maintained their glucose levels better than wild-type
mice, suggesting enhanced glucose production. In further
support for the enhanced hepatic gluconeogenic potential, we
found increased glycogen levels in the livers of moderately
fasted caveolin-1 null mice (Figure 3C). Upon refeeding, the
caveolin-1 null mice displayed fairly severe hyperglycemia and
a delayed suppression of FFA levels, further reflecting insulin
resistance and a poor adaption to altered metabolic conditions
(Figure 2F and Figure 3B). During a fast, the caveolin-1 null
mice lost considerably more body weight than did wild-type
mice (Figure 3D). CT analysis showed that the increased weight
loss was caused equally as much by loss of fat and lean body
mass (wild-type to caveolin-1 null mice, fat loss z0.6 versus
0.9 g, p = 0.18; lean body mass loss wild-type to caveolin-1
null mice,z1.7 versus 2.0 g, p = 0.11).
Enhanced Hepatic Gluconeogenesis in the Caveolin-1
Null Mouse
To further understand the underlying mechanism for the
enhanced glucose production, we compared the gene expres-
sion pattern in livers from 5 hr fasted wild-type and caveolin-1
null mice. Among the genes implicated in gluconeogenesis,
glucose-6-phosphatase and lactate dehydrogenase were tran-
scriptionally significantly upregulated in the caveolin-1 null
mice (Table S1). More strikingly, components of the urea cycle
were among the most upregulated genes in the caveolin-1 null
mice (Table S1). This may be a reflection of increased catabolism
of amino acids in caveolin-1 null livers. Consistent with the
hepatic gene expression profile, plasma urea levels were also
elevated in caveolin-1 null mice (Figure 3E), despite any signs
of muscle wasting in these animals (Mattsson et al., 2010; Razani
et al., 2002). The skeletal muscle tissue of caveolin-1 null mice
also has a much darker appearance (Figure S2A), indicative of
myotubes with increased mitochondrial content. There was an
overall downregulation of the mitochondrial transcriptional
program (Table S1). On the other hand, carnitine/acylcarnitine
translocase was upregulated, an indication of an increased flux
of fatty acylcarnitines and possibly an increased rate of incom-
plete fatty acid oxidation leading to elevated levels of acetyl-
CoA in the liver. In addition, a number of genes involved in perox-
isomal b-oxidation were upregulated in the caveolin-1 null mice
(Table S1). Peroxisomes are thought to mainly catabolize
branched-chain fatty acids and very long-chained fatty acids,
i.e., lipid species that cannot be efficiently transported into thec.
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Figure 3. Caveolin-1 Null Mice Have Increased Fasting Glucose Levels, Increased Breakdown of Amino Acids, and an Enhanced Response
to Phospodiesterase Inhibitor
(A and B) Shown are the levels of circulating insulin and glucose in the fed state at 7 p.m.; 24 hr fasted state at 7 p.m.; and 15, 30, and 60 min after refeeding.
(C) Glycogen levels in 5 hr fasted male mice (12 weeks old; n = 5 per group).
(D) Weight loss after 24 hr fasting.
(E and F) Circulating urea (E) and circulating as well as hepatic acetyl-carnitine levels (F) weremeasured in 5 hr male fastedmice (3months old; n = 7–9 per group).
Enoximone (10 mg/kg i.p.) was injected to 5 hr fasted male mice (4 months old; n = 3–5 per group).
(G and H) Enoximone-induced changes in glucose and glycerol levels. The error bars indicate SEM.
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However, peroxisomal fatty acid oxidation does not generate
ATP. Instead, each cycle of oxidation results in a shorter fatty
acid, acetyl-CoA, and H2O2. Accumulation of acetyl-CoA is the
main trigger for the activation of pyruvate carboxylase, which
in turn is an established positive regulator of gluconeogenesis.
In line with the transcriptional changes, acetylcarnitine levels,
which are a good reflection of the levels of acetyl-CoA (Carlin
et al., 1990), do indeed accumulate in the liver of caveolin-1
null mice (Figure 3F).
An important rate-limiting step for the rate of gluconeogenesis
is the enzyme fructose-1,6-bisphosphatase, whose activity is
dependent on its phosphorylation state regulated by a cAMP-Cell Mdependent kinase (el-Maghrabi et al., 1982). We therefore tested
the effects of a phospodiesterase inhibitor (enoximone) on
glucose levels. Enoximone very potently increases glucose
levels in caveolin-1 null mice, while the same dose had no effect
in the wild-type controls (Figure 3G). Enoximone also had no
effect on glycerol, FFA, and H2O2 levels in wild-type mice, while
caveolin-1 mice displayed increased glycerol, reduced FFA
levels, and increased H2O2 levels (Figure 3H and data not
shown). These dramatic physiological differences are likely due
to the availability of very high levels of gluconeogenic substrates
that allow these mice to mount a massive gluconeogenic
response the moment the animals face an increase in
hepatic cAMP levels. The increased glycerol levels indicateetabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inc. 175
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Caveolin-1 and Metabolic Flexibilitya concomitant enhancement of lipolysis, a reflection of the
enhanced sensitivity to cAMP in adipose tissue. This in turn is
linked to the reduced sensitivity to adrenergic stimulation at
the level of agonist-receptor interaction. In parallel, the excess
FFAs that are generated under these conditions are likely to be
metabolized and used as fuel for gluconeogenesis.
Hepatic fatty acid oxidation and gluconeogenesis are
processes that are tightly connected. Increased fatty acid
oxidation (e.g., by stimulation with PPARa agonists) has been
shown to enhance gluconeogenesis, while liver-specific
PEPCK/mice get enhanced hepatic steatosis due to a reduc-
tion in fatty acid oxidation (Burgess et al., 2004; Oosterveer
et al., 2009). Thus, changes in gluconeogenesis affect fatty
acid oxidation and vice versa. Therefore, we hypothesized
that the increased glucose production in the caveolin-1 null
mice is associated with an increase in hepatic fatty oxidation
that would explain the reduced fasting-induced steatosis. In
a first set of studies, we gave 3-mercaptopicolinic acid
(3-MPA), a specific PEPCK inhibitor (Goodman, 1975), to 5 hr
fasted wild-type and caveolin-1 null mice. 3-MPA exposure
caused a more dramatic drop in glucose levels in caveolin-1
null mice compared to wild-type mice, indicating that PEPCK-
dependent gluconeogenesis plays an important role in main-
taining normal glucose levels in moderately fasted caveolin-1
null mice (Figure 4A). As expected, in wild-type mice, there
was a small but continuous decrease in glucose levels
throughout the 3 hr time course. In contrast, the glucose levels
in the caveolin-1 null mice returned to baseline levels toward the
end of the time course. To obtain more insights into the
substrate flux in the caveolin-1 null mice, we followed the circu-
lating levels of insulin, glucagon, lactate, glycerol, and FFAs
over the same period. Insulin and glucagon levels were similar
in between wild-type and caveolin-1 null mice throughout the
time course (data not shown). Lactate and glycerol levels
were similar in wild-type and caveolin-1 null mice at baseline.
However, upon 3-MPA treatment, the levels of both lactate
and glycerol increased in the caveolin-1 null mice, while the
levels generally decreased in the wild-type mice (Figures 4B
and 4C). The increased lactate levels in the caveolin-1 null
mice indicate a preference for aerobic glycolysis as opposed
to oxidative phosphorylation. Thus, the normal baseline lactate
levels in caveolin-1 null mice may be a reflection of increased
production as well as increased use of lactate for gluconeogen-
esis in the liver. Alternatively, the elevated lactate levels reflect
a reduced uptake and utilization of lactate in the context of
PEPCK inhibition in the caveolin-1 nulls. The increase in the
glycerol levels in the caveolin-1 null mice suggests either
increased lipolysis and/or reduced use of glycerol for (PEPCK-
independent) gluconeogenesis. FFA levels remained fairly
constant and followed the glycerol levels in the wild-type
mice. In the caveolin-1 null mice, however, 3-MPA causes an
immediate drop in FFA levels followed by a slower recovery
(data not shown), indicating an increased use of these FFAs
(outside the liver) in response to the reduction in glucose.
Indeed, we observed an acylcarnitine fingerprint which is indic-
ative of an enhanced fatty acid oxidation in skeletal muscle that
may explain the reduction in FFA during both the 3-MPA and the
enoximone experiments (Adams et al., 2009) (Figure S2B). The
reduction in lactate and glycerol levels in wild-type mice follows176 Cell Metabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inthe anticipated metabolic adaptation to reduced PEPCK-
dependent gluconeogenesis, i.e., increased use of glycerol for
glucose production as well as reduced glycolysis due to a switch
to fatty acid oxidation.
To further explore the fasting response, we followed hepatic
steatosis for 24 hr in mice treated intermittently with 3-MPA or
vehicle. 3-MPA treatment increased fasting-induced steatosis
in caveolin-1 null mice to about the same levels as seen in
vehicle-treated wild-type mice. 3-MPA-treated wild-type mice
had evenmore aggravated fasting-induced steatosis (Figure 4D).
These are longitudinal measurements of hepatic lipid accumula-
tion using CT scanning of the liver, as described previously (As-
terholm and Scherer, 2010). Since the 3-MPA-treated mice had
increased hepatic triglyceride levels, we conclude that a reduc-
tion of PEPCK-mediated gluconeogenesis increases hepatic
steatosis through a reduction of hepatic fatty acid oxidation.
Chronically 3-MPA-treated caveolin-1 null mice still maintained
glucose levels better than wild-type mice (Figure 4E). This
suggests that caveolin-1 null mice are rapidly able to overcome
the acute hypoglycemic effects of 3-MPA, but this adaptive
response is not quite as effective an ‘‘enhancer’’ of hepatic fatty
acid oxidation as is the PEPCK-dependent gluconeogenesis in
the absence of 3-MPA.
The first step in PEPCK-dependent gluconeogenesis begins
in the mitochondria with the formation of oxaloacetate through
carboxylation of pyruvate. This reaction requires one molecule
of ATP and is catalyzed by pyruvate carboxylase, an enzyme
that is stimulated by high acetyl-CoA levels (Utter et al.,
1964). In contrast, glycerol enters the gluconeogenic pathway
through phosphorylation to glycerol-3-phosphate by glycerol
kinase and dehydrogenation to dihydroxyacetone phosphate
by glyceraldehyde-3-phosphate dehydrogenase. This pathway
requires less ATP and is not regulated by acetyl-CoA, and may
therefore be less tightly coupled to increased fatty acid oxida-
tion as compared to PEPCK-mediated gluconeogenesis.
Furthermore, an upregulation of the gluconeogenic pathway
may protect against hepatic steatosis through a reduced avail-
ability of glycerol for triglyceride synthesis. To test whether
caveolin-1 null mice have an enhanced ability to use glycerol
for glucose production, we injected 3-MPA-treated mice with
a bolus of glycerol. We found that the caveolin-1 null mice
indeed had enhanced glycerol-induced glucose production
(Figure 4F). However, glycerol clearance was delayed (Fig-
ure S3A). While we see a strong increase in gluconeogenesis,
other glycerol-consuming pathways, such as triglyceride
synthesis through glycerol kinase-induced conversion of glyc-
erol to glycerol-3-phospate, may be reduced in the caveolin-1
null mouse. Alternatively, an increased rate of lipolysis in the
caveolin-1 null mice would also explain the phenomenon. To
directly address the underlying mechanism for the reduction
in hepatic steatosis and the altered body composition in the
caveolin-1 null mice, we injected a tritium-labeled triolein lipid
emulsion intravenously in mice that have been fasted for 5 hr.
Under these conditions, 3H counts in the aqueous phase of all
collected tissues were similar in wild-type and caveolin-1 null
mice (data not shown). However, we found that the 3H counts
in the organic phase of the liver were reduced in the caveolin-1
null mice (Figure 5A). Thus, the reduction in hepatic steatosis
in the caveolin-1 null mice is best explained by a reducedc.
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Figure 4. Caveolin-1 Null Mice Display an Altered Response to the PEPCK Inhibition
Acute response to PEPCK inhibition: 12-week-old female cohorts were fasted for 5 hr at daytime prior to intragastric administration of 30 mg/kg 3-MPA (n = 5 per
group). Glucose levels were transiently lowered (A), while lactate (B) and glycerol (C) increased in the caveolin-1 null mice. Chronic response to PEPCK inhibition
was as follows: fasting-induced hepatic steatosis, followed by CT in female mice (8 months old; n = 5 per group), was aggravated in the presence of PEPCK
inhibitor (D). Glucose levels were measured at the end of the time course and remained higher in both PBS- and 3-MPA-treated caveolin-1 null mice (E). (F)
Glycerol-induced glucose production measured in PEPCK-inhibited female mice (3 months old; n = 4–5 per group) was higher in caveolin-1 nulls, indicating that
the higher glucose levels in caveolin-1 null mice during fasting are mediated by an increase in glycerol-induced gluconeogenesis. The error bars indicate SEM.
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Caveolin-1 and Metabolic Flexibilityhepatic triglyceride synthesis, although we cannot rule out
the possibility that an increase in fatty acid oxidation plays
a role during prolonged fasting as well. Surprisingly, we
also found that the 3H count in the organic phase of adiposeCell Mtissue was increased in the caveolin-1 null mice (Figure 5A).
This indicates an increase in triglyceride synthesis in adipose
tissue and strongly suggests that the reduced fat mass in the
caveolin-1 null mice is primarily due to enhanced lipolysis.etabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inc. 177
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Figure 5. Caveolin-1 Deficiency Results in Reduced Hepatic Triglyceride Synthesis, Increase in Reactive Oxygen Species, Elevated Adipose
Tissue FFAs, and Increased Macrophage Infiltration
(A) Intravenous infusion of 3H-triolein in mice fasted for 5 hr reveals a reduced hepatic triglyceride synthesis in the liver of caveolin-1 null mice. Note that the 3H
count in the organic phase of adipose tissue (BAT and IWAT) was increased in the caveolin-1 null mice. This indicates an increase in triglyceride synthesis rate.
(B and C) Circulating H2O2 and pyruvate levels in 2-month-old mice after 5 hr of fasting (n = 10–12 per group).
(D) Adiponectin and pyruvate levels measured in 4-month-old female mice were positively correlated.
(E) Local FFA levels from gonadal adipose tissue pieces (n = 4 + 4) obtained from 5-month-old females.
(F and G) Gonadal adipose tissue stained for mac2 and perilipin, respectively. The error bars indicate SEM.
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Null Mouse Is a Secondary Adaptation
To determine whether any of the reported metabolic changes in
the liver are a direct consequence of the lack of low level caveo-
lin-1 expression in hepatocytes, we used a newly generated
mouse model carrying a floxed version of the caveolin-1 gene
(Figures S3B and S3C), bred into the background of an albumin
promoter-driven CRE mouse. In this configuration, we eliminate
functional copies of the caveolin-1 gene exclusively from hepa-
tocytes. The gene is effectively rearranged in hepatocytes, but
not in other tissues (Figure S3D). We have assayed these mice
for fasting-induced steatosis and glycerol-induced glucose178 Cell Metabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inproduction and noted that these mice behaved similarly to
wild-type mice (Figure S3E). However, the glycerol levels
30 min after administration of 3-MPA were significantly lower in
liver-specific caveolin-1 nulls as compared to control mice (Fig-
ure S3F). Furthermore, over the course of a fasting/refeeding
experiment, there was a small but significant reduction in fasted
glucose levels in the mice lacking hepatic caveolin-1 (Fig-
ure S3G). Thus, despite a dramatic change in hepatic metabo-
lism in the full-body knockout mouse, the liver-specific caveo-
lin-1 null shows a slight defect in glucose production
associated with a more rapid clearance of glycerol, the opposite
phenotype observed in the full-body knockout animal. Wec.
Table 1. Most Profoundly Affected Canonical Pathways
Canonical Pathway P Value Ratio
Adipose Tissue
Mitochondrial dysfunction,
e.g., COX8B Y4.0, GPD2 Y1.6
5.00E-10 59/172
Oxidative phosphorylation,
e.g., ATP5A1 Y1.7, ATP5F1 Y1.6
6.86E-08 58/166
BCAA degradation, e.g., ACAA2 Y2.1,
BCKDHA Y1.3
3.62E-06 35/111
Liver
Urea dycle and metabolism of amino
groups, e.g., ASL [1.7, CPS [1.5
7.51E-05 7/80
Mitochondrial dysfunction,
e.g., COX7A Y1.1, NDUFA3 Y1.3
3.61E-06 15/173
Oxidative phosphorylation,
e.g., ATP 5E Y1.2, ATP5F1 [1.3
1.82E-04 13/167
Ratio: regulated genes/total genes in pathway.
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lipid droplet-associated caveolin-1, using full-body knockout
animals as controls (Figure S3H).
Based on these findings, we conclude that the elevated
glucose seen in the caveolin-1 null mice is not due to the actions
of caveolin within the liver, consistent with the very low expres-
sion level of caveolin-1 in hepatocytes. Instead we propose
that the glucose production is driven by higher substrate avail-
ability. Specifically, glycerol as a product of elevated lipolysis
seems to play a major role as a substrate of particular impor-
tance for the elevated glucose production in the caveolin-1 null
mice.
Altered Mitochondrial Function in Caveolin-1 Null
Adipose Tissue
We reasoned that both the enhanced gluconeogenesis in the
liver and the preservation of skeletal muscle in the whole-body
caveolin-1 null mouse could to a large extent be secondary
adaptations to changes in tissues that are rich in caveolin-1,
such as adipose tissue (Scherer et al., 1994). In a first attempt
to address this hypothesis, we investigated the gene expression
profile of gonadal white adipose tissue in caveolin-1 null versus
wild-type control mice. This analysis revealed a striking differ-
ence with respect to genes involved in mitochondrial function.
Most genes related to mitochondria, including branched-chain
amino acid (BCAA) catabolic enzymes, were downregulated in
the caveolin-1 null mice (Table 1). qPCR analysis of nuclear ex-
pressed mitochondrial genes in subfractionated fat pads
showed that the downregulation of the mitochondrial program
is predominantly seen in adipocytes, but not in the stromal
vascular fraction of adipose tissue (Table 1 and data not shown).
However, the protein levels of a key mitochondrial marker
(subunit IV of cytochrome oxidase) were similar in between
wild-type and caveolin-1 null mice, as judged by COXIV levels
per milligram total cellular protein (Figure S4A). We also exam-
ined the level of carbonylation in adipose tissue (a reflection of
oxidative damage recently established by Bernlohr and
colleagues [Frohnert et al., 2011; Grimsrud et al., 2008]) and
noticed elevated levels of oxidative damage (Figure S4B). InCell Mline with this finding, several redox-sensitive genes are reduced
in the gonadal adipose tissue of caveolin-1 null mice (Fig-
ure S4C). This includes glutathione S-transferase A4 (GSTA4),
the primary enzyme for lipid aldehyde detoxification, thereby ex-
plaining the elevated levels of carbonylated proteins. Mitochon-
drial function in adipocytes of GSTA4 null mice is significantly
impaired, even in the lean state (Curtis et al., 2010). In further
support for a presumed mitochondrial change, we observed
that caveolin-1 null mice had significantly increased circulating
peroxide levels (H2O2) in both males and females (Figure 5B).
Concomitant with that, we found a small but highly reproducible
decrease of circulating pyruvate levels (Figure 5C). H2O2
converts pyruvate to acetate (Babich et al., 2009). Hence, the
reduced levels of pyruvate may be a secondary consequence
to the increased presence of H2O2. In addition, we also found
a strong positive correlation between circulating pyruvate and
adiponectin levels in fasted mice across both genotypes in
wild-type and caveolin-1 null mice (Figure 5D). This provides
a mechanistic explanation for the lowered adiponectin levels in
the caveolin-1 nulls and ties these changes in adiponectin to
the profound metabolic changes seen in these mice. Increased
ROS levels and mitochondrial dysfunction in adipocytes have
been shown to reduce adiponectin levels by interfering with
the export of adiponectin through the secretory pathway (Koh
et al., 2007). We suggest that an increased pyruvate level is an
indicator of reduced ROS production and/or increased endoge-
nous antioxidative capacity, which has a positive impact on adi-
ponectin levels. While a causal relationship between these two
parameters in the context of oxidative stress remains to be
demonstrated, the strong correlations seen between pyruvate
and adiponectin hint at a potentially important physiological
connection prominently displayed in the caveolin-1 null mouse,
but also seen in wild-type mice. Finally, circulating H2O2 levels
and circulating adiponectin levels show a strong negative corre-
lation (Figure S4D), further establishing a tight link between the
local oxidative damage in adipose tissue and systemicmetabolic
adaptions.
Our in vivo characterization of the metabolic phenotype of the
caveolin-1 null mice indicates elevated lipolysis as a driving force
for the lean phenotype. Direct measurements of FFAs in adipose
tissue indeed reveal an approximately 2-fold elevation of FFAs in
caveolin-1 null adipose tissue as compared to wild-type adipose
tissue (Figure 5E). This finding is further supported by an
increased infiltration of macrophages, a phenomenon strongly
associated with elevated FFAs (Kosteli et al., 2010; Mottillo
et al., 2010). This is observed even in chow-fed caveolin-1 null
adipose tissue (Figure 5F). Moreover, HFD feeding leads to
a higher incidence of adipocyte death in caveolin-1 null mice
as judged by the increased occurrence of perilipin-negative
adipocytes (Figure 5G).
Mitochondrial function is challenging to assess directly in
adipose tissue, as the lipid-rich environment easily harms and/
or uncouples the mitochondrial during isolation procedures.
Therefore, we characterized the role of caveolin-1 in mitochon-
drial function in vitro using wild-type and caveolin-1 null mouse
embryonic fibroblasts (MEFs). We found that wild-type MEFs
were able to increase oxygen consumption in glucose-deprived
media, while caveolin-1 null MEFs displayed a preference for
glycolysis. To achieve that, we have altered the relative contentetabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inc. 179
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Figure 6. Altered Mitochondrial Function in Cav-1 Null Cells
(A) Caveolin-1/MEFs display a preference for glycolysis. Cells were incubated in various concentrations (in mM) of pyruvate (P) and glucose (G) as indicated.
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured in a Seahorse XF flux analyzer.
(B) Caveolin-1 null cells have a higher mitochondrial membrane potential as judged by TMRM fluorescence intensity.
(C) Comparison of wild-type and caveolin-1 null dicarboxylate carrier (mDIC) mRNA levels in MEFs, adipose tissue, and liver. All measurements reflect triplicate
measurements.
(D) BCAA levels after 5 hr of fasting in 2-month-old mice (n = 10–12 per group).
(E) Phospho-mTOR levels were measured in m. gastrocnemius in 5 hr fasted, 3-month-old male mice (n = 6 per group).
(F) Shown is schematic representation of caveolin-1 null phenotype: caveolin-1 deficiency leads to a reduced sensitivity to insulin and adrenergic agonists and
elevated basal lipolysis, and is associated with altered mitochondrial function in adipose tissue. These defects have a profound impact on whole-body
metabolism. In the caveolin-1 null mice, we observe a dramatically enhanced hepatic glucose production as well as an increase in BCAA levels (likely due to
increased food intake). We hypothesize that the elevated lipolysis and the alteredmitochondrial function in adipose tissue (and possibly other tissues) expose the
liver to elevated levels of gluconeogenic substrates. The elevated BCAA levels both enhance fatty acid oxidation and increase anabolic processes in skeletal
muscle. The error bars indicate SEM.
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degree of acidification of the supernatants and compared it to
the rate of oxygen consumption (Figure 6A). This finding is
consistent with the initial in vivo observations of this study180 Cell Metabolism 15, 171–185, February 8, 2012 ª2012 Elsevier In(e.g., increased RER during fasting and buildup of lactate upon
PEPCK inhibition) that suggest an altered mitochondrial metab-
olism. In line with a recently published study (Bosch et al., 2011),
we also found that caveolin-1 null MEF mitochondria displayc.
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controls (Figure 6B). We have previously shown that a modest
overexpression of the mitochondrial dicarboxylate carrier
(mDIC), an inner mitochondrial membrane carrier, results in
hyperpolarization of mitochondria and increased oxidative
damage (Das et al., 1999). Interestingly, caveolin-1 null MEFs
have significantly higher mDIC mRNA expression compared to
wild-type MEFs (Figure 6C). Even though we do not know
whether this increase in mitochondrial membrane potential is
also present in caveolin-1 null adipocytes, we do see a significant
2-fold increase in the levels of themDICmRNA in adipose tissue,
while the levels in liver are similar in wild-type and caveolin-1 null
mice (Figure 6C). Similar observations were made at the protein
level. The more marked mDIC expression difference in adipose
tissue as compared to MEFs may depend on the stimulatory
effect of FFAs on mDIC expression in vivo (Das et al., 1999).
Thus, the local increase in FFAs contributes to the mitochondrial
alterations in caveolin-1 null adipose tissue and is associated
with increased ROS-mediated damage. These defects in turn
cause the widespread increased occurrence of adipocyte death
found in the adipose tissue of caveolin-1 null mice.
Mitochondria isolated in the context of in vitro experiments
showed similar mitochondrial function in both liver and lung (a
caveolin-1-rich tissue) from wild-type and caveolin-1 null mice
(Figures S5A and S5B). Thus, even though caveolin-1 null
MEFs display mitochondrial alterations, our data suggest that
altered mitochondrial function is not a ubiquitous phenomenon
in caveolin-1 null tissues. Alternatively, the alterations in mito-
chondrial function in caveolin-1 null cells could be secondary
to defects of other cellular functions (e.g., lipid trafficking) and
therefore are only apparent in the context of intact cells.
Elevated Circulating BCAA Levels in Caveolin-1 Null
Mice
Kahn and colleagues have recently shown that changes in the
levels of BCAA-catabolizing enzymes exclusively in adipose
tissue have an impact on systemic levels of BCAAs (Herman
et al., 2010). We found an increase in circulating levels of BCAAs
in the caveolin-1 null mice (Figure 6D). BCAAs are essential
amino acids that are important for muscle growth by both stim-
ulating anabolic pathways in general and serving as building
blocks for muscle proteins (Blomstrand et al., 2006; Yamamoto
et al., 2010). In fact, a recent study shows that administration
of BCAA reverses dexamethasone-induced muscle atrophy (Ya-
mamoto et al., 2010). Thus, the elevated circulating levels of
BCAA may explain why lean body mass is preserved despite
the increased rate of gluconeogenesis in the caveolin-1 null
mice. BCAAs can stimulate muscle anabolism through the
mTOR pathway involving the mTORC1 complex. Consistent
with this mechanism, we found that phospho-mTOR levels
were elevated in m. gastrocnemius in caveolin-1 null mice (Fig-
ure 6E). The mTOR pathway can also upregulate mitochondrial
function, but overactivation of this pathway can lead to insulin
resistance. Insulin-resistant muscle cannot dispose of glucose
as well and has to rely more on fatty acid oxidation to meet its
energy requirements. The serum acylcarnitine profile in fasted
state and the increased glucose levels in refed caveolin-1 null
mice are both consistent with enhanced mitochondrial function
and reduced insulin-induced glucose disposal in muscle. ThereCell Mare several possible mechanisms that could explain this differ-
ence in circulating BCAAs. These relate to the fact that caveo-
lin-1 null mice have an increase in food intake, have a reduced
fat mass, and also show a transcriptional downregulation of
BCAAs metabolizing enzymes in adipose tissue. To determine
whether the transcriptional change was associated with
a reduced catabolism and use of BCAAs in adipose tissue of
the caveolin-1 null mice, we administrated tritium-labeled
leucine to fed and mildly fasted mice (Figures S6A and S6B).
As expected, we found that the fed state is associated with
a 10-fold increase in tritium counts in the organic phase, indi-
cating that leucine is a significant lipogenic substrate in adipose
tissue. To our surprise, the adipose tissues of the caveolin-1 null
mice were taking up more leucine than wild-type adipose
tissues, and this difference was more prominent in the lipid
(organic) phase. In mildly fasted mice, the increase in tritium
counts in adipose tissue of the caveolin-1 nulls was observed
in all three phases, indicating an overall increase in leucine
metabolism. Nevertheless, if the difference in body composition
is taken into account, the overall tissue leucine uptake is similar
between the wild-type and the caveolin-1 null mice. We
conclude therefore that the transcriptional reduction of BCAA-
catabolizing enzymes in adipose tissue reflects a negative feed-
back rather than a functional defect of these enzymes and that
the increase in circulating BCAA levels is largely due to the
increase in dietary intake in the caveolin-1 null mice.
DISCUSSION
Systemic loss of caveolin-1 leads to a complex metabolic
phenotype including a substantial decrease in metabolic flexi-
bility. This is also tightly associated with lower adiponectin levels
and, in particular, lower levels of the HMW form of adiponectin. In
fact, mice overexpressing adiponectin and mice lacking caveo-
lin-1 display metabolic phenotypes at two opposite extremes of
the spectrum of metabolic responses. At least part of this
complex metabolic phenotype of the caveolin-1 null mouse is
a compensatory response to severe metabolic dysregulation at
the level of adipocytes. Importantly, reconstituting caveolin-1
expression in the endothelium in the context of a full-body cav-
eolin-1 null mouse did not restore the metabolic phenotype,
but did improve cardiovascular and pulmonary hypertension
phenomena, hence eliminating another likely cell type that could
have contributed to a metabolic phenotype (Murata et al., 2007).
Caveolin-1 null adipose tissue is insensitive to both insulin and
adrenergic agonists, likely due to the lack of caveolin-1, the
key structural protein of caveolae in adipocytes that stabilizes
the receptors and facilitates signaling (Liu et al., 2002). As judged
by the enhanced response to the phosphodiesterase inhibitor
enoximone, downstream signaling at the level of adrenergic
agonists and glucagon appears to function properly, even in
the absence of caveolin-1. Nevertheless, a high degree of meta-
bolic inflexibility persists in the caveolin-1 null mouse. Our data
suggest that this is not only due to a very complex set of changes
that lead to the inability to accurately gauge the metabolic needs
of the system, but is also caused by altered mitochondrial
function.
Lack of caveolin-1 is associated with altered mitochondrial
function at multiple levels. Caveolin-1 null MEFs display anetabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inc. 181
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membrane potential. In vivo, we observe elevated circulating
levels of H2O2 and an increased buildup of lactate upon PEPCK
inhibition in caveolin-1 null mice. In caveolin-1 null adipose
tissue, we observe increased oxidative damage and an
increased susceptibility to HFD-induced adipocyte death.
Gene expression analysis also shows altered expression of
many mitochondrial and redox-sensitive genes in adipose
tissue, but not in the liver. At this point, we do not know whether
the altered mitochondrial function is a consequence of the meta-
bolic changes in the caveolin-1 null mice or if caveolin-1 defi-
ciency directly has an impact on mitochondrial function. There
are several potential mechanisms that can lead to the altered
mitochondrial function observed in caveolin-1 null cells. One
possibility is that the increased local levels of adipose tissue
FFAs, driven by widespread elevated lipolysis in caveolin-1 null
adipocytes, directly induce mitochondrial dysregulation and
ROS production (a mechanism recently reviewed in Vigouroux
et al., 2011). Several additional studies have highlighted that
the rate of mitochondrial peroxide generation is significantly
higher when basal respiration is driven by fatty acid oxidation
compared to carbohydrate-based substrates (Anderson et al.,
2007; St-Pierre et al., 2002). Previous studies from our laboratory
show that FFAs can lead to an increase in mDIC, higher levels of
which in turn elevate the mitochondrial potential (Das et al.,
1999). In line with a cause/effect relationship, caveolin-1 null
MEFs and adipose tissue display elevated mDIC levels.
Increased membrane potential per se can be the cause for
increased ROS production, leading to mitochondrial and meta-
bolic dysfunction. Thus, the phenomenon of increased mito-
chondrial membrane potential may not necessarily directly
depend on excess FFA levels in these cells. A second possibility
is the mechanism suggested by Bosch and colleagues. They
report an increase in mitochondrial cholesterol accumulation
and a reduction in mitochondrial GSH in caveolin-1-deficient
cells and suggest that this leads the mitochondrial impairments
in these cells (Bosch et al., 2011). It is also possible that intracel-
lular dysregulation of lipid species other than cholesterol plays
a role for the mitochondrial phenotype. Sphingolipids, such as
ceramides, may show an altered subcellular distribution and
play a role in this context. However, we mainly detect signs of
mitochondrial alteration in adipose tissue, but not in other tissues
where caveolin-1 is also expressed at high levels, such as the
lung. This suggests that altered intracellular lipid partitioning
alone cannot fully explain the mitochondrial alterations in caveo-
lin-1 null mice. Hence, our present hypothesis that best explains
our findings is that adipose tissue-resident cells are more vulner-
able to mitochondrial changes induced by caveolin-1 deficiency
through the elevated exposure of FFAs.
The elevated RER in caveolin-1 null mice suggests that the
preference for glucose is not only an in vitro phenomenon, but
is also evident at the whole system level. Despite the increased
use of glucose, the caveolin-1 null mice are not only able tomain-
tain, but have, in fact, higher fasting glucose levels than the wild-
type controls. This is due to a vastly increased capacity for
hepatic glucose production. In particular, we observe an
increased capacity to produce glucose from glycerol in the cav-
eolin-1 null mice. However, the elevated levels of circulating urea
also suggest that the glucose overproduced in the caveolin-1182 Cell Metabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Innull mouse is in part generated from an enhanced amino acid
catabolism. In general, enhanced amino acid catabolism leads
to muscle wasting. However, caveolin-1 null mice do not have
reduced muscle mass. There may well be several mechanisms
underlying this complex phenotype, but we chose to focus on
secondary adaptations due to the severe defects observed in
the adipose tissue (this study and Cohen et al., 2003, 2004; Ra-
zani et al., 2002). Our rationale to this approach was mainly that
the liver-specific caveolin-1 null mice lack a substantial liver
phenotype, and that the reported muscle phenotype of the cav-
eolin-1 null mouse appears to be more pronounced as the mice
age (Schubert et al., 2007).
From gene expression profile analysis of adipose tissue, we
found that the pathway for BCAA catabolism is downregulated.
On the contrary, our leucine tracer studies showed that leucine
is more effectively taken up and used in the lipogenic pathway
in caveolin-1 null adipose tissue compared to wild-types. Thus,
the transcriptional reduction of BCAA-metabolizing enzymes
results from a negative feedback mechanism and is not the
cause of the higher circulating BCAA levels in the caveolin-1
null mice. Moreover, we confirm that excess dietary BCAAs
feed into the lipogenic pathway in mature adipocytes (Frerman
et al., 1983). BCAAs are not only an important metabolic building
block and precursor, but have been shown to stimulate anabolic
pathways through the mTOR-pathway. Furthermore, isoleucine
prevents accumulation of triglycerides in liver and muscle
through a mechanism that involves upregulation of PPARa and
UCPs, resulting in increased fatty acid oxidation (Nishimura
et al., 2010). On the other hand, elevated BCAAs in diet-induced
obesity have recently been shown to induce insulin resistance as
a consequence of chronic activation of the mTOR pathway
(Newgard et al., 2009). All these effects assigned to BCAAs fit
very well with the phenotype of the caveolin-1 null mouse. The
muscles of the caveolin-1 null mouse display enhanced mito-
chondrial proliferation (Schubert et al., 2007) and elevated levels
of phospo-mTOR, and the brown adipose depot has elevated
levels of UCP1 (Mattsson et al., 2010). However, we do not
exclude the possibility that caveolin-1 may also play a direct
role for insulin resistance and mitochondrial proliferation in the
skeletal muscle in caveolin-1 null mice, as also suggested by
Oh, Schubert, and colleagues (Oh et al., 2008; Schubert et al.,
2007). The main findings of our study are summarized in
Figure 6F.
What is the Relevance of the Caveolin-1 Null Mouse
for Human Biology and Disease?
There are a few reports on caveolin-1 deficiency leading to lip-
odystrophy, but this condition is very rare (Garg and Agarwal,
2008). However, a relative decrease in caveolin-1 and ‘‘caveolar
dysfunction’’ has been suggested to play a role in the metabolic
syndrome (Fernandez-Real et al., 2010; Venugopal et al., 2004).
Obese subjects have also been shown to display elevated
levels of BCAAs (Newgard et al., 2009). Moreover, several
studies suggest that mitochondrial dysfunction in adipose
tissue contributes to metabolic disturbances associated with
obesity (De Pauw et al., 2009; Maassen, 2006). It may be that
enhanced glucose production in insulin-resistant states is
further aggravated by factors and metabolic alterations origi-
nating from suboptimal mitochondrial function in adiposec.
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nism for the lower adiponectin levels in the caveolin-1 null
mice, but the altered mitochondrial function (leading to an
altered energetic state of the adipocyte) and the increased
levels of reactive oxygen species are likely contributing factors
(Koh et al., 2007; Sun et al., 2009). In this study, we discovered
a striking positive correlation between pyruvate and adiponec-
tin, which may be related to the antioxidant capacity of pyru-
vate. Further detailed studies are required to fully understand
the regulation of adiponectin levels as well as the specific role
of mitochondrial alterations in adipose tissue for systemic meta-
bolic disease.
Many tumor cells lose caveolin-1 in the early phase of transfor-
mation, and caveolin-1 is well-known for its tumor suppressor
activity through inhibition of several anabolic pathways (Williams
and Lisanti, 2005). However, a high rate of proliferation requires
enhanced aerobic glycolysis as opposed to oxidative phospory-
lation. Thus, altered mitochondrial function associated with loss
of caveolin-1 may contribute to an increase in glycolysis and
thereby enable proliferation. The overall metabolic environment
of the full-body caveolin-1 null knockout may therefore predis-
pose cells to transformation. In fact, Lisanti and colleagues
have proposed a model in which loss of caveolin-1 in tumor-
associated fibroblasts increases oxidative stress and causes
increased tumor growth (Trimmer et al., 2011). We support that
hypothesis, and the full caveolin-1 null mouse indeed displays
elevated circulating H2O2 levels. Moreover, tumor growth
depends on high influx of nutrients such as glucose and BCAAs
and is inhibited by pyruvate. This demand is met by an
upregulation of various nutrient transporters and a selective
decrease in the sodium-coupled monocarboxylate transporter
1 (SMCT1) that primarily transports butyrate and pyruvate, which
are inhibitors of histone deacetylases and thereby can induce
tumor cell apoptosis (Ganapathy et al., 2009). Thus, the
increased levels of BCAAs and glucose, and the reduced levels
of pyruvate, may also promote tumor progression in the caveo-
lin-1 null mouse.
In summary, caveolin-1 null mice are lean and muscular but
show a decreased metabolic flexibility and an increased predis-
position for malignant transformation, ultimately leading to
a shorter life span (Park et al., 2003). Our data suggest that the
complex phenotype of the caveolin-1 null mouse to a large
extent depends on metabolic and mitochondrial alterations at
the level of the adipocyte. The metabolic adaptations that occur
in the caveolin-1 null micemay serve as amodel for the effects of
changes in mitochondrial function observed in obesity as well as
in cancer metabolism.EXPERIMENTAL PROCEDURES
Animals
Caveolin-1 null mice and liver-specific caveolin-1 null mice were used on
the FVB background. The strategy for the generation of the liver-specific
caveolin-1 null mice is shown in Figure S3B. All micewere backcrossed at least
ten times to their respective backgrounds. Mice were maintained on a 12 hr
dark/light cycle and housed in groups of two to four with unlimited access to
water, chow (number 5058, Lab-Diet), or HFD (number D12492, Research
Diets Inc.) as indicated for the individual experiments. The Institutional Animal
Care and Use Committee of the University of Texas Southwestern Medical
Center, Dallas, has approved all animal experiments.Cell MAdiponectin Size Fractionation
Analysis of the adiponectin complex distribution was performed as described
in Schraw et al. (Schraw et al., 2008) and analyzed using a rabbit polyclonal
anti-mouse adiponectin primary antibody (Scherer et al., 1995).
b3-AR Agonist Sensitivity Test
Tail vein serum samples were obtained before and 5, 15, and 60 min after an
intraperitoneal injection of 1 mg/kg CL 316,243 (Sigma, Sigma Aldrich, USA).
Hepatic Steatosis Measurements
Quantification of hepatic steatosis was performed by CT as previously
described (Asterholm and Scherer, 2010). In brief, mice were anesthetized
with isoflurane, and a CT scan was performed at a resolution of 93 mm using
the short scan mode (180) on an eXplore Locus in vivo MicroCT Scanner
from GE Healthcare. Liver lipid content was estimated by obtaining the
average CT value in multiple regions well within the liver, as validated in Aster-
holm and Scherer (2010).
Liver Histology
A subset of livers were fixed in methanol-free 4% paraformaldehyde for 20–
24 hr, cryoprotected with sequential 10% and 18% sucrose equilibrations
for 12 hr each at 4C, and then cryoembedded in optimal cutting temperature
medium (OCT, Sakura Finetek, USA). Multiple plane 8 mm thickness cryostat
sections were prepared of each liver and temporarily stored at80C. Staining
for lipids with oil red O was conducted according to established histologic
protocol (Sheehan and Hrapchak, 1980).
3-MPA Treatment
3-MPA (Toronto Research Chemicals Inc.) was dissolved in PBS, and
30 mg/kg was given orally at the indicated time points.
Glycerol Tolerance Test
Thirty minutes after an oral dose of 30 mg/kg 3-MPA, the mice were injected
i.p. with 1 g/kg glycerol (0.1 g/mL in PBS). Tail vein serum samples were
obtained just prior to and 15, 30, 60, and 120 min after the glycerol injection.
Metabolic Response to Phospodiesterase Inhibitor
The mice were fasted for 5 hr prior to i.p. injection with 10 mg/kg enoximone
(Sigma) dissolved in 2%Tween in PBS. Tail vein serum samples were obtained
before and 30, 60, 120, and 180 min after the injection.
Blood and Tissue Biochemistry
Insulin and adiponectin levels were measured by commercial ELISA kits (Milli-
pore, USA). Glucagon levels were measured in protease inhibitor-treated
blood samples with a Millipore RIA kit. Glucose and glycerol levels were deter-
mined with Sigma Diagnostics Glucose Reagents and Free Glycerol Reagent
(Sigma, Sigma Aldrich, USA). FFA levels were measured with NEFA-HR(2)
(Wako Pure Chemical Industries, Japan) and triglycerides with Infinity reagent
(Thermo Scientific, USA). Urea was measured with a Vitros 250 Analyzer.
Lactate, pyruvate, hydrogen peroxide, BCAAs, and glycogen were all
measured by commercial kits (BioAssay Systems and Biovision). Local FFA
levels in adipose tissue were measured by mincing 50 mg freshly dissected
gonadal adipose tissue. To break membranes, minced tissue samples were
put in ice-cold hypotonic buffer (10mMTRIS-HCl [pH 7.5]) and passed through
a 22G syringe. The homogenates were centrifuged (1,0003 g, 5 min) at +4C,
and FFAs were measured in the infranatant.
Metabolic and Mitochondrial Analysis of MEFs
For the experiments with wild-type and caveolin null MEFs, cells were isolated
from 13.5 day embryos and maintained in low-glucose DMEM plus 10% FCS.
The day before the experiment, 40,000 cells were plated in XF24 V7 cell culture
microplates. On the day of the experiment, the media was replaced
with unbuffered XF assay media equilibrated for 1 hr and transferred to a
temperature-controlled (37C) Seahorse analyzer to measure the basal
oxygen consumption rate. To measure the mitochondrial content and mito-
chondrial membrane potential, cells were trypsinized and labeled 30 min at
37C with mitotracker (200 nM) or tetramethylrhodamine methyl esteretabolism 15, 171–185, February 8, 2012 ª2012 Elsevier Inc. 183
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Caveolin-1 and Metabolic Flexibility(TMRM, 0.2 mg/ml) in PBS. The cells were washed by centrifugation with PBS
and analyzed in the FL2 channel of a FACSCalibur instrument.
3H-Triolein Uptake and Oxidation
For tissue-specific lipid uptake and lipid oxidation analyses, 3H-triolein was
tail-vein-injected into mice following a 5 hr fast. After 15 min, tissues were har-
vested and lipids were extracted using a chloroform-to-methanol-based
extraction method. Samples were then counted for radioactivity.
Statistical Analysis
Data are generally expressed asmean ± standard error of themean (SEM). The
Student’s t test was used for comparisons between groups, log-transforma-
tion was performed as necessary to obtain normal distribution, and *p <
0.05 was considered as significant; **p < 0.01; ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.cmet.2012.01.004.
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